NOTCH1 and B-cell chronic lymphocytic leukemia: These data were subsequently confirmed in a homogeneously prospective CLL series that underwent rituximab consolidation after first-line therapy; in this study, patients carrying NOTCH1 mutations were characterized by lower rate of complete remission and response duration while in rituximab maintenance [17].